WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
US$12,56
arrow_upward
+0,48%(+0,060) 1D
16 ຕ.ລ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for WXXWY...
Open
US$12,29
High
US$12,56
Low
US$12,20
Mkt. cap
198,43 ຕື້
Avg. vol.
61,89 ພັນ
Volume
110,85 ພັນ
52-wk high
US$14,80
52-wk low
US$7,30
Beta
0,01
Shares outstanding
2,06 ຕື້
No. of employees
15 ພັນ
Open
US$12,29
High
US$12,56
Low
US$12,20
Mkt. cap
198,43 ຕື້
Avg. vol.
61,89 ພັນ
Volume
110,85 ພັນ
52-wk high
US$14,80
52-wk low
US$7,30
Beta
0,01
Shares outstanding
2,06 ຕື້
No. of employees
15 ພັນ
News stories
From web sources and news partners
Yahoo! Finance Canada
·
26 ນາທີກ່ອນ
NTHI,TRIN,HERZ,EFOR,FFIN,GO,NXRT,AVBC,BLCO,CULP,VSNT,VIRC,KWY,ENTX,BLIN,GRNT,SSP,GAIA,AFCG,NRGV,APCX,THRY,KLTR,BETR | Stock Prices | Quote Comparison
Foreign Policy Journal
·
55 ນາທີກ່ອນ
Super Micro Computer (NASDAQ: SMCI) Signals Were Visible Before Its Stock 45% Rally
AOL.com
·
7 ຊົ່ວໂມງກ່ອນ
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
MarketWatch
·
6 ຊົ່ວໂມງກ່ອນ
These surprising stocks could be some of the biggest drivers of S&P 500 earnings growth
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About Wuxi Biologics Cayman ADR